A New Paradigm for Immune Modulation
Immunyx is a drug development company focused on neutrophil modulation in disease.
The Challenge:
Neutrophil Therapy
Neutrophils are the most populous immune cell, yet few advances have been made in modulating their disease-causing activity.
Large pharma is working on neutrophil therapies such as Danirixin and Navarixin.
Currently there are no FDA approved neutrophil therapies due to Neutropenia, systemic toxicity and difficulty reaching neutrophils at target location.
The Need
Effective and safe treatments to prevent deregulated neutrophil damage in numerous large market diseases.
COPD
251m Cases
3.1m Deaths
$11B Market
Cancer
27.5m Cases
9.6m Deaths
$158B Market
Colitis
9m Cases
$10.25B Market
Arthritis
20m Cases
$60B Market
Our Technology:
Modulating Neutrophil Toxicity in Chronic Disease
Neutrophil modulation using novel pharmacological approaches